Titre : Cytochrome P-450 CYP1B1

Cytochrome P-450 CYP1B1 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Patient Reported Outcome Measures
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cytochrome P-450 CYP1B1 : Questions médicales les plus fréquentes", "headline": "Cytochrome P-450 CYP1B1 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cytochrome P-450 CYP1B1 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-12", "dateModified": "2025-03-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cytochrome P-450 CYP1B1" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Famille-1 de cytochromes P450", "url": "https://questionsmedicales.fr/mesh/D000072461", "about": { "@type": "MedicalCondition", "name": "Famille-1 de cytochromes P450", "code": { "@type": "MedicalCode", "code": "D000072461", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.422.220.453.100" } } }, "about": { "@type": "MedicalCondition", "name": "Cytochrome P-450 CYP1B1", "alternateName": "Cytochrome P-450 CYP1B1", "code": { "@type": "MedicalCode", "code": "D065633", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Purnima Singh", "url": "https://questionsmedicales.fr/author/Purnima%20Singh", "affiliation": { "@type": "Organization", "name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)." } }, { "@type": "Person", "name": "Shubha Ranjan Dutta", "url": "https://questionsmedicales.fr/author/Shubha%20Ranjan%20Dutta", "affiliation": { "@type": "Organization", "name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)." } }, { "@type": "Person", "name": "Chi Young Song", "url": "https://questionsmedicales.fr/author/Chi%20Young%20Song", "affiliation": { "@type": "Organization", "name": "From the Department of Pharmacology, Addiction Science, and Toxicology, College of Medicine, University of Tennessee Health Science Center, Memphis (P.S., S.R.D., C.Y.S.)." } }, { "@type": "Person", "name": "Frank J Gonzalez", "url": "https://questionsmedicales.fr/author/Frank%20J%20Gonzalez", "affiliation": { "@type": "Organization", "name": "Laboratory of Metabolism, National Cancer Institute, Bethesda, MD (F.J.G.)." } }, { "@type": "Person", "name": "Kafait U Malik", "url": "https://questionsmedicales.fr/author/Kafait%20U%20Malik", "affiliation": { "@type": "Organization", "name": "" } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Ankle fractures: a systematic review of patient-reported outcome measures and their measurement properties.", "datePublished": "2022-06-18", "url": "https://questionsmedicales.fr/article/35716224", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11136-022-03166-3" } }, { "@type": "ScholarlyArticle", "name": "Properties of Patient-Reported Outcome Measures in Recessive Stargardt Disease.", "datePublished": "2022-09-21", "url": "https://questionsmedicales.fr/article/36130585", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000527093" } }, { "@type": "ScholarlyArticle", "name": "Association between clinician reported outcome and patient reported outcome measures one year after stroke.", "datePublished": "2023-05-11", "url": "https://questionsmedicales.fr/article/37178516", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jstrokecerebrovasdis.2023.107156" } }, { "@type": "ScholarlyArticle", "name": "Conscientious use of patient-reported outcome measures in supportive care.", "datePublished": "2023-03-22", "url": "https://questionsmedicales.fr/article/36947341", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00520-023-07681-y" } }, { "@type": "ScholarlyArticle", "name": "Patient-reported measures outcomes: modern evaluation of oral health.", "datePublished": "2023-07-18", "url": "https://questionsmedicales.fr/article/37464376", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12903-023-03219-0" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Hémoprotéines", "item": "https://questionsmedicales.fr/mesh/D006420" }, { "@type": "ListItem", "position": 5, "name": "Cytochromes", "item": "https://questionsmedicales.fr/mesh/D003580" }, { "@type": "ListItem", "position": 6, "name": "Cytochrome P-450 enzyme system", "item": "https://questionsmedicales.fr/mesh/D003577" }, { "@type": "ListItem", "position": 7, "name": "Famille-1 de cytochromes P450", "item": "https://questionsmedicales.fr/mesh/D000072461" }, { "@type": "ListItem", "position": 8, "name": "Cytochrome P-450 CYP1B1", "item": "https://questionsmedicales.fr/mesh/D065633" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cytochrome P-450 CYP1B1 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cytochrome P-450 CYP1B1", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cytochrome P-450 CYP1B1", "description": "Comment diagnostiquer une anomalie de CYP1B1 ?\nQuels tests sont utilisés pour évaluer CYP1B1 ?\nQuels symptômes indiquent un problème avec CYP1B1 ?\nY a-t-il des marqueurs biologiques pour CYP1B1 ?\nLe diagnostic de CYP1B1 est-il complexe ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Patient+Reported+Outcome+Measures&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cytochrome P-450 CYP1B1", "description": "Quels symptômes sont liés à une mutation de CYP1B1 ?\nLes symptômes de CYP1B1 varient-ils selon les individus ?\nCYP1B1 peut-il affecter le métabolisme des médicaments ?\nQuels signes cliniques sont associés à CYP1B1 ?\nLes symptômes de CYP1B1 sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Patient+Reported+Outcome+Measures&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cytochrome P-450 CYP1B1", "description": "Comment prévenir les troubles liés à CYP1B1 ?\nLe mode de vie influence-t-il CYP1B1 ?\nDes vaccinations peuvent-elles aider avec CYP1B1 ?\nLe suivi médical régulier est-il important pour CYP1B1 ?\nLes conseils génétiques sont-ils utiles pour CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Patient+Reported+Outcome+Measures&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cytochrome P-450 CYP1B1", "description": "Quels traitements existent pour les troubles liés à CYP1B1 ?\nPeut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?\nY a-t-il des traitements préventifs pour CYP1B1 ?\nLes traitements sont-ils efficaces pour tous les patients ?\nDes thérapies alternatives sont-elles disponibles pour CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Patient+Reported+Outcome+Measures&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cytochrome P-450 CYP1B1", "description": "Quelles complications peuvent survenir avec CYP1B1 ?\nLes complications de CYP1B1 sont-elles graves ?\nComment gérer les complications liées à CYP1B1 ?\nLes complications de CYP1B1 sont-elles prévisibles ?\nY a-t-il des complications à long terme avec CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Patient+Reported+Outcome+Measures&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cytochrome P-450 CYP1B1", "description": "Quels sont les facteurs de risque pour CYP1B1 ?\nL'hérédité joue-t-elle un rôle dans CYP1B1 ?\nL'exposition à des toxines influence-t-elle CYP1B1 ?\nLe sexe influence-t-il les risques liés à CYP1B1 ?\nL'alimentation a-t-elle un impact sur CYP1B1 ?", "url": "https://questionsmedicales.fr/mesh/D065633?mesh_terms=Patient+Reported+Outcome+Measures&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie de CYP1B1 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses enzymatiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer CYP1B1 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de métabolisme des médicaments et les analyses sanguines sont courants." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec CYP1B1 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des troubles métaboliques ou des réactions médicamenteuses peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques pour CYP1B1 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux de certains métabolites peuvent indiquer une dysfonction." } }, { "@type": "Question", "name": "Le diagnostic de CYP1B1 est-il complexe ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Il peut être complexe, nécessitant une évaluation clinique et des tests spécialisés." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une mutation de CYP1B1 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles oculaires, des anomalies de développement et des cancers peuvent apparaître." } }, { "@type": "Question", "name": "Les symptômes de CYP1B1 varient-ils selon les individus ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction de la gravité de la mutation." } }, { "@type": "Question", "name": "CYP1B1 peut-il affecter le métabolisme des médicaments ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une dysfonction de CYP1B1 peut entraîner des réactions indésirables aux médicaments." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à CYP1B1 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des troubles de la vision et des anomalies cutanées peuvent être observés." } }, { "@type": "Question", "name": "Les symptômes de CYP1B1 sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent être gérés, mais d'autres peuvent être permanents." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés à CYP1B1 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut le dépistage génétique et l'éducation sur les risques." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il CYP1B1 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut réduire les risques de complications liées à CYP1B1." } }, { "@type": "Question", "name": "Des vaccinations peuvent-elles aider avec CYP1B1 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les troubles liés à CYP1B1." } }, { "@type": "Question", "name": "Le suivi médical régulier est-il important pour CYP1B1 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier permet de détecter précocement les complications." } }, { "@type": "Question", "name": "Les conseils génétiques sont-ils utiles pour CYP1B1 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils aident à comprendre les risques et à planifier des mesures préventives." } }, { "@type": "Question", "name": "Quels traitements existent pour les troubles liés à CYP1B1 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent inclure des thérapies géniques et des médicaments spécifiques." } }, { "@type": "Question", "name": "Peut-on traiter les effets secondaires des médicaments liés à CYP1B1 ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des ajustements de dosage et des alternatives médicamenteuses peuvent aider." } }, { "@type": "Question", "name": "Y a-t-il des traitements préventifs pour CYP1B1 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils génétiques et un suivi régulier peuvent être des mesures préventives." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour tous les patients ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité des traitements peut varier selon la gravité de la condition." } }, { "@type": "Question", "name": "Des thérapies alternatives sont-elles disponibles pour CYP1B1 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certaines thérapies alternatives peuvent être explorées, mais leur efficacité n'est pas prouvée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec CYP1B1 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme des cancers et des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Les complications de CYP1B1 sont-elles graves ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être graves et nécessiter une intervention médicale." } }, { "@type": "Question", "name": "Comment gérer les complications liées à CYP1B1 ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut un suivi médical, des traitements symptomatiques et des interventions." } }, { "@type": "Question", "name": "Les complications de CYP1B1 sont-elles prévisibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être prévisibles avec un suivi approprié." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme avec CYP1B1 ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour CYP1B1 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et l'exposition environnementale." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans CYP1B1 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les mutations de CYP1B1 peuvent être héritées, augmentant le risque de troubles." } }, { "@type": "Question", "name": "L'exposition à des toxines influence-t-elle CYP1B1 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certaines toxines peut affecter l'activité de CYP1B1." } }, { "@type": "Question", "name": "Le sexe influence-t-il les risques liés à CYP1B1 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent que le sexe peut influencer l'expression de CYP1B1." } }, { "@type": "Question", "name": "L'alimentation a-t-elle un impact sur CYP1B1 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes alimentaires peuvent influencer l'activité de CYP1B1 et le métabolisme." } } ] } ] }

Sources (10000 au total)

Ankle fractures: a systematic review of patient-reported outcome measures and their measurement properties.

Ankle fractures are commonly occurring fractures, especially in the aging population, where they often present as fragility fractures. The disease burden and economic costs to the patient and society ... Searches were performed in CINAHL, EMBASE, Medline and Google Scholar from the date of inception to July 2021. Studies that assessed the measurement properties of a PROM in an adult ankle fracture pop... In total, 13 different PROMs were identified in the 23 included articles. Only the Ankle Fracture Outcome of Rehabilitation Measure (A-FORM) presented some evidence on content validity. The Olerud-Mol... The absence of validation studies covering all measurement properties of PROMs used in the adult ankle fracture population precludes the recommendation of a specific PROM to be used in the evaluation ...

Properties of Patient-Reported Outcome Measures in Recessive Stargardt Disease.

The study aimed to explore the psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI VFQ) and Impact of Vision Impairment (IVI) profile in recessive Stargardt diseas... The NEI VFQ-25 and IVI-28 were administered to individuals with STGD1. Responses were analyzed following psychometrically established dimension structures of the NEI VFQ (visual function [VF] subscale... Seventy-one participants (42 females, 29 males; mean age, 44 ± 19 years) were included. Self-reported difficulty levels were lower than the mean difficulty of items in both instruments. Person reliabi... The NEI VFQ and IVI have acceptable psychometric properties in STGD1 with the IVI allowing more sensitive person stratification. Targeting of questionnaires to individuals with STGD1 might be improved...

Association between clinician reported outcome and patient reported outcome measures one year after stroke.

Patient reported outcome measures (PROM) are increasingly important in the evaluation of care. In this study we evaluate patient PROM in stroke patients and the association with clinical reported outc... Of 3706 first-ever stroke patients, 1861 were discharged home and invited to fill out PROM at discharge, 90 days and one-year after stroke. PROM include mental and physical health and patients' self-r... 844 (45%) of the invited stroke patients filled out PROM. In general, those patients were younger and less severely affected (higher Barthel index and lower mRS). Compliance after enrolment is about 7... Participation rate to fill out PROM is only 45% among stroke patients who were discharged home, and compliance rate is around 75% up one-year follow-up. PROM associated with the clinician reported fun...

Conscientious use of patient-reported outcome measures in supportive care.

Patient-reported outcome measures (PRO) are critical tools to developing an understanding of cancer patients' experience. This paper presents some of the lesser-understood implications of using patien... This study uses a combination of literature sources, real-world examples from supportive care studies, and statistical simulations to demonstrate the operating characteristics of patient-reported meas... It is demonstrated that care must be taken in the analysis of PROs as the assumptions of the most common mean-based approaches are often violated including linearity, normally distributed errors, inte... PRO-based studies must be designed conscientiously as each PRO item will demonstrate a varying degree of subjectivity in a given population. Sample sizes of randomized studies using PROs must be infla...

Patient Reported Outcome Measures for Salivary Function: A Systematic Review.

A number of patient-reported outcome measures (PROMs) assess quality of life and symptom severity in patients with salivary gland dysfunction, but many vary in the extent of validation and domain type... PubMed, Web of Science, Embase, PsycInfo, and CINAHL.... A systematic review was performed using Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Validated instruments with >1 item to assess salivary gland-related symp... A total of 2059 abstracts were retrieved, and 133 full-text articles were reviewed. Sixteen PROMs assessing xerostomia (n = 7), sialadenitis (n = 4), Sjogren's syndrome (n = 2), Parkinson's-associated... Several PROMs evaluate salivary function. The abilties of these PROMs to meet design and validation standards were variable, with notable limitations in content validity for all tools. New and updated... N/A Laryngoscope, 133:1796-1805, 2023....

A systematic review of patient-reported outcome measures in paediatric endocrinology.

Patient reported outcome measures (PROMs) are useful tools in paediatric endocrinology to gauge health status in children, especially since they are often unable to clearly communicate it themselves. ... We identified PROMs in paediatric endocrinology by systematically searching the Cochrane Library, MEDLINE, World Health Organisation International Clinical Trials Registry Platform, and the Cumulative... We identified 5003 papers in the initial search. After applying exclusion criteria we included seven PROMs in the review. Six PROMs were specific to Type I Diabetes and one to Hypothyroidism. We gave ... The scope and quality of PROMs in paediatric endocrinology is limited. Further research and development of PROM tools are required in paediatric endocrinology to allow for improved patient care....

Stroke survivors' preferences on assessing patient-reported outcome measures.

To assess quality of life and unmet needs after stroke, patient-reported outcome measures (PROMs) have gained increasing attention. However, patients' perspectives on assessing PROMs remain unclear, p... A paper-based questionnaire was sent to stroke survivors treated at the Department of Neurology, University of Leipzig, Germany. Health-related quality of life (HRQoL, EQ-5D-5L) and preferences regard... 158 persons were contacted and 80 replies were subsequently analyzed. Mean age was 70.16 years and mean HRQoL was 68.79 (visual analogue scale with a theoretical maximum of 100). Participants showed p... For the first time, this study showed individual preferences on assessing PROMs after ischemic stroke, focusing on the way, time interval, duration, and initiation site of surveys. These insights migh...

Cutoff Values of MASK-air Patient-Reported Outcome Measures.

In clinical and epidemiological studies, cutoffs of patient-reported outcome measures can be used to classify patients into groups of statistical and clinical relevance. However, visual analog scale (... To calculate cutoffs for VAS global, nasal, ocular, and asthma symptoms.... In a cross-sectional study design of all MASK-air participants, we compared (1) approaches based on the percentiles (tertiles or quartiles) of VAS distributions and (2) data-driven approaches based on... We assessed 395,223 days from 23,201 MASK-air users with self-reported allergic rhinitis. The percentile-oriented approach resulted in lower cutoff values than the data-driven approach. We obtained co... Using a data-driven approach, we were able to define cutoff values for MASK-air VASs on allergy and asthma symptoms. This may allow for a better classification of patients with rhinitis and asthma acc...

Patient-reported outcome measures for patellofemoral disorders: a systematic review.

Patellofemoral conditions include, but are not limited to, anterior knee pain syndrome and patellar instability. Patients and surgeons may find it difficult to identify the specific source of the symp... A systematic review was conducted, searching for scientific articles relating to PROMs in patellofemoral conditions, from inception to July 2022. Scoring systems including physician-directed or imagin... Twenty-two relevant PROMs were encountered, divided into four categories: eight PROMs for anterior knee pain syndrome, five for patellar instability, four for other patellofemoral conditions and five ... While many PROMs have been found used in patellofemoral research, only few of them have showed sufficient methodological quality. In addition, PROMs employed in PF literature are often inaccurately ch... Level II....